These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28920949)

  • 1. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.
    Mahindra A; Hari P; Fraser R; Fei M; Huang J; Berdeja J; Callander N; Costa L; Diaz MA; Freytes C; Gale RP; Girnius S; Holmberg L; Kharfan-Dabaja M; Kumar S; Kyle R; Lazarus H; Lee C; Maiolino A; Moreb J; Nishihori T; Pawarode A; Saad A; Savani BN; Schriber J; William B; Wirk BM; Krishnan A; Nieto Y; D'Souza A
    Bone Marrow Transplant; 2017 Dec; 52(12):1616-1622. PubMed ID: 28920949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
    Munshi PN; Vesole D; Jurczyszyn A; Zaucha JM; St Martin A; Davila O; Agrawal V; Badawy SM; Battiwalla M; Chhabra S; Copelan E; Kharfan-Dabaja MA; Farhadfar N; Ganguly S; Hashmi S; Krem MM; Lazarus HM; Malek E; Meehan K; Murthy HS; Nishihori T; Olin RL; Olsson RF; Schriber J; Seo S; Shah G; Solh M; Tay J; Kumar S; Qazilbash MH; Shah N; Hari PN; D'Souza A
    Cancer; 2020 Dec; 126(23):5077-5087. PubMed ID: 32965680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
    Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
    Badros A; Barlogie B; Siegel E; Roberts J; Langmaid C; Zangari M; Desikan R; Shaver MJ; Fassas A; McConnell S; Muwalla F; Barri Y; Anaissie E; Munshi N; Tricot G
    Br J Haematol; 2001 Sep; 114(4):822-9. PubMed ID: 11564069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
    Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT
    BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
    Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
    Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
    Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melphalan 200 mg/m
    Sweiss K; Patel S; Culos K; Oh A; Rondelli D; Patel P
    Bone Marrow Transplant; 2016 Oct; 51(10):1337-1341. PubMed ID: 27183094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.
    Dhakal B; Nelson A; Guru Murthy GS; Fraser R; Eastwood D; Hamadani M; Pasquini M; D'Souza A; Hari P
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):165-172. PubMed ID: 28159578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
    Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
    Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
    Munshi PN; Vesole DH; St Martin A; Davila O; Kumar S; Qazilbash M; Shah N; Hari PN; D'Souza A
    Cancer; 2021 Nov; 127(22):4233-4239. PubMed ID: 34374445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma.
    Talamo G; Rakszawski KL; Rybka WB; Dolloff NG; Malysz J; Berno T; Zangari M
    Eur J Haematol; 2012 Aug; 89(2):145-50. PubMed ID: 22540279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
    Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
    Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.
    Parikh GC; Amjad AI; Saliba RM; Kazmi SM; Khan ZU; Lahoti A; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Popat U; Alousi AM; Champlin RE; Giralt SA; Qazilbash MH
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):812-6. PubMed ID: 19539212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allografting or autografting for myeloma.
    Rajkumar SV; Kyle RA
    N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17600891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.